Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial)
- 1 January 2005
- journal article
- clinical trial
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 95 (1), 1-7
- https://doi.org/10.1016/j.amjcard.2004.08.054
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Clinical outcomes of patients with diabetes mellitus and acute myocardial infarction treated with primary angioplasty or fibrinolysisHeart, 2002
- effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patientsJournal of the American College of Cardiology, 2002
- Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non–ST-Segment-Elevation Acute Coronary SyndromesCirculation, 2001
- Patency of Percutaneous Transluminal Coronary Angioplasty Sites at 6-Month Angiographic Follow-UpCirculation, 2001
- Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb angioplasty substudyJournal of the American College of Cardiology, 2000
- Abciximab reduces mortality in diabetics following percutaneous coronary interventionJournal of the American College of Cardiology, 2000
- Emerging concepts in the management of acute myocardial infarction in patients with diabetes mellitusJournal of the American College of Cardiology, 2000
- Restenosis, late vessel occlusion and left ventricular function six months after balloon angioplasty in diabetic patientsJournal of the American College of Cardiology, 1999
- The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantationJournal of the American College of Cardiology, 1998
- Predictive Factors of Restenosis After Coronary Stent PlacementJournal of the American College of Cardiology, 1997